- Home
- ALAR vs IMUX Comparison
ALAR vs IMUX Comparison
Compare ALAR & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALAR
- IMUX
- Stock Information
- Founded
- ALAR 2013
- IMUX 2016
- Country
- ALAR Israel
- IMUX United States
- Employees
- ALAR N/A
- IMUX N/A
- Industry
- ALAR Computer Software: Prepackaged Software
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- ALAR Technology
- IMUX Health Care
- Exchange
- ALAR Nasdaq
- IMUX Nasdaq
- Market Cap
- ALAR 94.0M
- IMUX 86.3M
- IPO Year
- ALAR 2018
- IMUX N/A
- Fundamental
- Price
- ALAR $6.91
- IMUX $1.17
- Analyst Decision
- ALAR Strong Buy
- IMUX Strong Buy
- Analyst Count
- ALAR 2
- IMUX 6
- Target Price
- ALAR $24.00
- IMUX $12.67
- AVG Volume (30 Days)
- ALAR 116.1K
- IMUX 850.6K
- Earning Date
- ALAR 03-13-2025
- IMUX 03-04-2025
- Dividend Yield
- ALAR N/A
- IMUX N/A
- EPS Growth
- ALAR N/A
- IMUX N/A
- EPS
- ALAR 0.10
- IMUX N/A
- Revenue
- ALAR $31,561,000.00
- IMUX N/A
- Revenue This Year
- ALAR $22.82
- IMUX N/A
- Revenue Next Year
- ALAR $9.87
- IMUX N/A
- P/E Ratio
- ALAR $7.03
- IMUX N/A
- Revenue Growth
- ALAR 40.80
- IMUX N/A
- 52 Week Low
- ALAR $6.78
- IMUX $0.92
- 52 Week High
- ALAR $46.69
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- ALAR 17.37
- IMUX 59.92
- Support Level
- ALAR $6.78
- IMUX $1.00
- Resistance Level
- ALAR $8.50
- IMUX $1.32
- Average True Range (ATR)
- ALAR 0.51
- IMUX 0.10
- MACD
- ALAR -0.24
- IMUX 0.03
- Stochastic Oscillator
- ALAR 3.25
- IMUX 53.19
About ALAR Alarum Technologies Ltd.
Alarum Technologies Ltd is a company engaged in the information security business. The company has two Internet access segments which include Enterprise Internet Access and Consumer Internet Access. Its Enterprise Internet Access offers web data collection and a private Internet browsing platform and Consumer Internet Access provides solutions for secure and private Internet browsing. Geographically, the company has a presence in the UK Virgin Islands, Israel, Europe, APAC, MEA, Hong Kong, the USA, and others, and generates a majority of its revenue from the APAC followed by the United States.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.